Dateline City:
KENILWORTH, N.J.
Results from Interim Analysis of Phase 2 KEYNOTE-052 Study to be Presented at ESMO 2016 Congress and Highlighted in ESMO Press Program
First Presentation of Data Investigating KEYTRUDA in the Front Line Treatment of Bladder Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced positive findings from the phase 2 KEYNOTE-052 study
investigating the use of KEYTRUDA (pembrolizumab), the
companys anti-PD-1 therapy, in previously untreated patients with
unresectable (inoperable) or metastatic urothelial cancer who are
ineligible for cisplatin-based therapy.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more